Issue 63 November - December 2014

Treatment of skin rash and pruritus induced by biological therapies

Skin rash and itchy skin are known to be common side-effects in patients treated with EGFR and tyrosine kinase inhibitors, and can be distressing, particularly when severe. A growing understanding of why this happens is leading to new ways of managing the problem

Read More ...
Issue 63 November - December 2014

Mindfulness: a way to live life in the present tense

“I have learned to shift from seeing myself as invulnerable to quite vulnerable – and to know that as not something to push away. There are good things about vulnerability. I have never felt so loved, supported, treasured… and have come to know some people in a way I think I never would otherwise.”

Read More ...
Issue 63 November - December 2014

Age discrimination at a time of health rationing: unthinkable or common sense?

Karol Sikora, a medical oncologist who has directed cancer services at a major London hospital, triggered an angry reaction earlier this year when he suggested that younger patients should have priority when it comes to accessing very expensive, potentially life extending, cancer therapies. But did he have a point? we asked Ulrich Wedding, a specialist in cancer in the elderly and a board member of the International Society of Geriatric Oncology, to debate the issue with Sikora to see if they could find any common ground

Read More ...
Issue 63 November - December 2014

Inside India's cancer epidemic

Epidemiologists have long been warning of the rapid rise in cancer rates hitting low- and middle-income countries. But it takes a journalist to get across how those statistics are playing out in peopleÂ’s lives. Jason Gale, who covers Asian Healthcare for Bloomberg Markets, received a Best Cancer Reporter Award for his piece on the cost of cancer in India, reprinted below.

Read More ...
Issue 63 November - December 2014

Biology in the bunker

Advances in imaging and molecular biology are opening up a wealth of new avenues for research and treatment in radiotherapy. But could progress be held back by a lack of public awareness of the potential for innovation?

Read More ...